- Stocks
- Pharma & Healthcare
- Kabra Drugs
Kabra Drugs share price
NSE: KABRADGPharma & HealthcareDrug Manufacturers - Specialty & Generic
Kabra Drugs at a glance
With a market capitalisation of ₹56 Cr, it ranks 3006th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was −4.4% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹35 Cr and net profit ₹1 Cr (+171.8%), on a standalone basis.
Key numbers
- Market cap
- ₹56 CrRank 3006 on NSE
- Price to book
- 1.07×FY25
- EPS (TTM)
- ₹2.09to Q4 FY26
- ROE
- −4.4%FY25
- ROCE
- −4.4%FY25
- Debt to equity
- 0.02FY25
- Net profit margin
- 0.0%FY25
- Book value / share
- ₹10.40FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Kabra Drugs quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | ₹7 Cr | ₹20 Cr | ₹30 Cr | ₹35 Cr |
| Revenue YoY | — | — | — | — | — | — | — | — |
| Net profit | −₹1 Cr | −₹0 Cr | −₹1 Cr | ₹0 Cr | −₹1 Cr | ₹2 Cr | ₹3 Cr | ₹1 Cr |
| Net profit YoY | — | — | — | — | — | — | — | +171.8% |
| Net margin | — | — | — | — | −7.0% | 9.3% | 8.4% | 3.0% |
| EPS | −₹1.24 | −₹3.94 | −₹0.53 | ₹0.21 | −₹0.21 | ₹0.77 | ₹1.08 | ₹0.45 |
Kabra Drugs financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Operating profit | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹1 Cr | −₹1 Cr |
| Net profit | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹1 Cr | −₹1 Cr |
| EPS (₹) | −₹0.14 | −₹0.41 | −₹0.42 | −₹0.77 | −₹1.66 | −₹0.99 |
| Cash from operations | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹5 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹1 Cr | −₹1 Cr | ₹25 Cr |
Kabra Drugs shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Non-institutions | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Kabra Drugs vs peers
The listed Pharma & Healthcare companies nearest to Kabra Drugs by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ROYALRoyal Sense | — | — | — | ₹59 Cr | — | — |
| BACPHARBacil Pharma | — | — | — | ₹58 Cr | — | — |
| VEERHEALTHVeerhealth Care | — | — | — | ₹58 Cr | — | — |
| CONSTRONICConstronics Inf | — | — | — | ₹57 Cr | — | — |
| KABRADGKabra Drugs | — | — | — | ₹56 Cr | — | — |
| BANDARAMBandaram Pharma | — | — | — | ₹53 Cr | — | — |
| VRLVasundhara Ras | — | — | — | ₹53 Cr | — | — |
Ask anything about Kabra Drugs
Pivot answers on the live chart with evidence you can check, and tests strategies against KABRADG's own history. Try: “Why has KABRADG moved over the last three months?” · “Backtest a 50-day moving-average crossover on KABRADG over five years” · “Compare KABRADG with ROYAL on margins and valuation”
Frequently asked questions about Kabra Drugs
What is the market cap of Kabra Drugs?
Kabra Drugs' market capitalisation is ₹56 Cr (₹56 Cr) at the 22 Oct 2026 close, ranking 3006th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Kabra Drugs?
Return on equity was −4.4% in FY25 and return on capital employed was −4.4% in FY25 (standalone figures).
Is Kabra Drugs a debt-free company?
Kabra Drugs is close to debt-free: its debt-to-equity ratio was 0.02 in FY25.
What were Kabra Drugs' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Kabra Drugs reported revenue of ₹35 Cr and net profit of ₹1 Cr, +171.8% year on year.
What is the shareholding pattern of Kabra Drugs?
As of 30 Jun 2026: non-institutions 100.00%.
Who are Kabra Drugs' competitors?
The listed Pharma & Healthcare companies closest to Kabra Drugs by market cap are Royal Sense, Bacil Pharma, Veerhealth Care, Constronics Inf, Bandaram Pharma and Vasundhara Ras.
Is Kabra Drugs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Kabra Drugs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on KABRADG against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with K · all NSE stocks · this page as text